Compare · FRMM vs JNJ
FRMM vs JNJ
Side-by-side comparison of Forum Markets Incorporated (FRMM) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRMM and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $662.49B, about 13529.0x FRMM ($49.0M).
- Over the past year, FRMM is down 82.4% and JNJ is up 44.7% - JNJ leads by 127.1 points.
- JNJ has been more active in the news (17 items in the past 4 weeks vs 5 for FRMM).
- JNJ has more recent analyst coverage (25 ratings vs 1 for FRMM).
- Company
- Forum Markets Incorporated
- Johnson & Johnson
- Price
- $3.45-6.38%
- $273.25-0.69%
- Market cap
- $49.0M
- $662.49B
- 1M return
- -25.65%
- +5.62%
- 1Y return
- -82.43%
- +44.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 5
- 17
- Recent ratings
- 1
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest FRMM
- Forum Edge AI Announces $94.4 Million Definitive AI Cloud Services Compute Agreement with Fireworks
- SEC Form 8-K filed by Forum Markets Incorporated
- Forum Announces Third Quarter 2026 Earnings Release Date and Webcast Details
- Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Forum Markets Announces Joint Venture with Edge Node AI to Deploy Inference AI Compute Across the U.S. at Existing Powered Data Sites and Mobile Communications Towers
- Forum Markets Incorporated filed SEC Form 8-K: Leadership Update
- Forum Markets Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Sidoti Events, LLC's August Micro-Cap Virtual Conference
- Chief Executive Officer Rudisill Mcandrew covered exercise/tax liability with 98,174 shares, decreasing direct ownership by 5% to 1,786,805 units (SEC Form 4) (for withholding tax)
- SEC Form 10-Q filed by Forum Markets Incorporated
Latest JNJ
- Johnson & Johnson to Host Enterprise Business Review
- SEC Form 13F-HR filed by Johnson & Johnson
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
- Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
- Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
- SEC Form 10-Q filed by Johnson & Johnson
- Johnson & Johnson downgraded by Erste Group
- Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
- SEC Form 8-K filed by Johnson & Johnson